Guillermo Garcia‐Manero

The University of Texas MD Anderson Cancer Center (US)

Research Areas

Discover Papers by Guillermo Garcia‐Manero

Access 250+ million papers and cite this researcher's work with AI assistance

Try AnswerThis Free →

H-index

149

Publications

2933

Citations

88943

i10-index

1019

Publications & Citations Over Time

Top Cited Publications

Want to find and read papers by this researcher? AnswerThis gives you instant access.

Title	Year	Citations
Revised International Prognostic Scoring System fo...	2012	3079
Clinical Effect of Point Mutations in Myelodysplas...	2011	1612
Phase 1 study of low-dose prolonged exposure sched...	2003	813
Acute myeloid leukemia: current progress and futur...	2021	727
Genetic Alterations Activating Kinase and Cytokine...	2012	716
Genetic characterization of TET1, TET2, and TET3 a...	2009	714
Results of a randomized study of 3 schedules of lo...	2006	688
New Comprehensive Cytogenetic Scoring System for P...	2012	684
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myel...	2013	674
<i>CCAT2</i>, a novel noncoding RNA mapping to 8q2...	2013	609

Publications

1.
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Year: 2012Citations: 3079DOI: 10.1182/blood-2012-03-420489
2.
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Year: 2011Citations: 1612DOI: 10.1056/nejmoa1013343
3.
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
Year: 2003Citations: 813DOI: 10.1182/blood-2003-03-0687
4.
Acute myeloid leukemia: current progress and future directions
Year: 2021Citations: 727DOI: 10.1038/s41408-021-00425-3
5.
Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia
Year: 2012Citations: 716DOI: 10.1016/j.ccr.2012.06.005
6.
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
Year: 2009Citations: 714DOI: 10.1182/blood-2009-03-210039
7.
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
Year: 2006Citations: 688DOI: 10.1182/blood-2006-05-021162
8.
New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge
Year: 2012Citations: 684DOI: 10.1200/jco.2011.35.6394
9.
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents
Year: 2013Citations: 674DOI: 10.1038/leu.2013.355
10.
<i>CCAT2</i>, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer
Year: 2013Citations: 609DOI: 10.1101/gr.152942.112

About Guillermo Garcia‐Manero

Guillermo Garcia‐Manero is a researcher with 2933 publications and 88943 citations. They are affiliated with The University of Texas MD Anderson Cancer Center. Their research focuses on . With an h-index of 149, they are among the top researchers in their field.

Citation Distribution

Distribution of citations across publications

Research Smarter

AnswerThis uses AI to help you search, understand, and cite research from Guillermo Garcia‐Manero and 250M+ other papers.

AI-powered research assistance
Automatic citations and references
Advanced academic writing tools

Research Area Breakdown

Publication Types

Publication type data not available

Impact Metrics Over Time

Citations per publication by year